Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oncology
Pharma
Karyopharm reports Xpovio miss, FDA filing in separate cancers
Reporting a new miss in one cancer indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another.
Fraiser Kansteiner
Jul 31, 2026 10:00am
Fierce Biotech
How India can build on its budding innovative R&D moment: report
Jul 23, 2026 5:00am
Roche tops cancer reputation rankings as AstraZeneca climbs back
Jul 2, 2026 6:00am
FDA finds fault with Pinnacle’s photodynamic therapy videos
Jun 25, 2026 10:12am
AstraZeneca spells out a cancer screening strategy with the YMCA
Jun 25, 2026 4:30am
Obesity meds, China drive $2T in projected 2032 drug sales: report
Jun 23, 2026 9:00am
More News
Verastem mulls options on approved asset in pancreatic cancer
Jun 17, 2026 3:00pm
Behind the headlines of ASCO 2026
Jun 5, 2026 9:38am
Pharma urged to adapt support to changing patient populations
May 29, 2026 6:45am
AbbVie scores FDA green light for another ImmunoGen asset
May 28, 2026 7:27am
See more stories
